SCHEMBL4244119

SCHEMBL4244119

COC(=O)c1occ(COC(=O)Nc2ccccc2)c1-c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 2/20 0.44
TDP1 Q9NUW8 1/20 0.43
LMNA P02545 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ENPP2 Q13822 2/20 0.40
POLB P06746 2/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2D6 P10635 3/20 0.40
CYP2C19 P33261 3/20 0.40
ALDH1A1 P00352 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C9 P11712 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977057 0.79 PTGS1 (0.42) LMNARAB9ASMN1; SMN2TP53HTT
SCHEMBL3977656 0.76 TACR1 (0.41) TDP1LMNARAB9ASMN1; SMN2TP53
SCHEMBL3977524 0.74 GCGR (0.36) MGLLTDP1NPC1RAB9ASMN1; SMN2
SCHEMBL6555726 0.73 MAPK8 (0.41) LMNARAB9ASMN1; SMN2ALDH1A1
SCHEMBL3977063 0.72 LMNA (0.45) TDP1LMNARAB9ASMN1; SMN2NPSR1
SCHEMBL4284113 0.71 MEN1 (0.49) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL3985267 0.69 MGLL (0.44) MGLLTDP1LMNANPC1RAB9A
SCHEMBL3977117 0.69 ALDH1A1 (0.48) LMNARAB9ASMN1; SMN2TP53MAPT
SCHEMBL3981715 0.68 PTGS1 (0.41) LMNARAB9ASMN1; SMN2TP53MAPT
SCHEMBL25348086 0.68 MGLL (0.54) MGLLNPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MGLL 710/4885TDP1 3923/4885LMNA 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.